BioSpace News Archive

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a partnership with Epic, the industry leading healthcare software company, to integrate Myriad’s full line of genetic tests with Epic’s expansive network of 600,000 physicians and more than 250 million patients.

According to Report, the global catheter stabilization devices market size is expected to be worth around USD 2.68 billion by 2030 from valued at USD 1.50 billion in 2020 and is projected to grow at a CAGR of 7.8% during the forecast period 2022 to 2030.

According to Vision Research Reports, the global artificial intelligence in medical imaging market is projected to grow at a CAGR of 36% during the forecast period 2022 to 2030 and to reach valuation of USD 20.1 billion by 2030.

Calithera Biosciences, Inc. (Nasdaq: CALA), announced that the first patient has been enrolled in a multicenter phase 2 clinical trial evaluating its spleen tyrosine kinase (SYK) inhibitor mivavotinib (CB-659) in patients with relapsed/refractory non-germinal center B-cell like (non-GCB) diffuse large B-cell lymphoma (DLBCL), a DLBCL subpopulation that primarily comprises patients with activated B-cell like disease (ABC).

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), the Company’s next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.

Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company will participate at the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 28, 2022.

According to Report Study, the global fill-finish pharmaceutical contract manufacturing market was surpassed at USD 8.2 billion in 2021 and is expected to hit around USD 14.3 billion by 2030, growing at a CAGR of 6.37% from 2022 to 2030.

As per Vision Research Reports, The global Fitness Tracker market size is expected to be worth around US$ 148.7 billion by 2030 from valued at US$ 40.6 billion in 2020 and is anticipated to grow at a CAGR of 20.9% during forecast period 2021 to 2030.

VistaGen Therapeutics, Inc. (Nasdaq: VTGN), today reported its financial results for its fiscal year ended March 31, 2022 and provided a corporate update.

According to Vision Research Reports, the Moist Wound Dressings market size was reached at US$ 4.2 billion in 2021 and is expected to be worth around US$ 6.9 billion by 2030, poised to grow at a CAGR of 6.8% during forecast period 2022 to 2030.